Q0245 — Injection, bamlanivimab and etesevimab, 2100 mg
Q0245 is a HCPCS Level II code for injection, bamlanivimab and etesevimab, 2100 mg. It belongs to the Temporary Codes section. It was terminated on December 13, 2023 and is not valid on new claims.
This code has been terminated
CMS terminated Q0245 on December 13, 2023. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q0245
- Long descriptor
- Injection, bamlanivimab and etesevimab, 2100 mg
- Short descriptor
- Bamlanivimab and etesevima
- Added
- February 9, 2021
- Terminated
- December 13, 2023
- BETOS
- O1G
- Pricing indicator
- 54 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Vaccinations.
Codes adjacent to Q0245
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q0245 is not quite right, the correct code is very often within a few positions of it.
- Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
- Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0239Injection, bamlanivimab-xxxx, 700 mgterminated
- Q0240Injection, casirivimab and imdevimab, 600 mgterminated
- Q0243Injection, casirivimab and imdevimab, 2400 mgterminated
- Q0244Injection, casirivimab and imdevimab, 1200 mgterminated
- Q0247Injection, sotrovimab, 500 mgterminated
- Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0478Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
- Q0479Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0480Driver for use with pneumatic ventricular assist device, replacement only
- Q0481Microprocessor control unit for use with electric ventricular assist device, replacement only
- Q0482Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Questions about Q0245
What is HCPCS code Q0245?
Q0245 is a HCPCS Level II code for injection, bamlanivimab and etesevimab, 2100 mg. It sits in the Temporary Codes section.
Does Medicare cover Q0245?
The CMS HCPCS file marks Q0245 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q0245 still valid?
No. Q0245 was terminated on December 13, 2023 and should not be used on new claims.